Synonyms: BCD 132 | BCD-132 | Ivlizi®
divozilimab is an approved drug (Russia (2023))
Compound class:
Antibody
Comment: Divozilimab (BCD 132) is an anti-CD20 monoclonal antibody that was developed by Biocad.
|
Classification ![]() |
|
Compound class | Antibody |
Approved drug? | Yes. Russia (2023) |
International Nonproprietary Names ![]() |
|
INN number | INN |
11336 | divozilimab |
Synonyms ![]() |
BCD 132 | BCD-132 | Ivlizi® |
Database Links ![]() |
|
Specialist databases | |
IMGT/mAb-DB | 1060 |
Other databases | |
GtoPdb PubChem SID | 491299869 |
Search PubMed clinical trials | divozilimab |
Search PubMed titles | divozilimab |
Search PubMed titles/abstracts | divozilimab |